| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
HEIDELBERG, Germany & CAMBRIDGE, U.K.—Expedeon AG recently announced the closing of an agreement with Abcam plc for the sale of Expedeon’s proteomics and immunology business, as announced on Nov. 11, 2019, and as approved by the extraordinary shareholder meeting held a little over a month later. The closing triggers a payment of €120 million by Abcam to Expedeon. Consequently, Expedeon AG also moved to change its company name to 4basebio AG.
 
“We are now commencing a new chapter in the company's development with a new name, a new business focus and excellent funding resulting from this transaction. Referring to the four base building blocks of all genetic material, the new company name 4basebio AG reflects our new DNA-based business focus. We will also continue with our successful buy-and-build strategy,” said Dr. Heikki Lanckriet, CEO of the company.
 
Under its future name 4basebio, Expedeon will focus activities in the field of genomics, building on the expertise in its Spanish business unit, Expedeon S.L.U. in Madrid. The company will focus on DNA manufacturing to supply DNA products for therapeutic and other uses requiring large amounts of high-purity DNA, such as the fast-growing market of novel gene therapies and gene vaccines.
 
Reportedly, the high need for DNA caused by wide adoption of gene therapies and gene vaccines will likely drive the synthetic biology market to $38.7 billion by 2020, with a compound annual growth rate of 44.2 percent. Besides DNA manufacturing, 4basebio aims to provide research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase and DNA primase enzymes, addressing the research tools and diagnostic products markets.

Related Topics

Published In

Volume 16 - Issue 1 | January 2020

January 2020

January 2020 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue